Pharmalink raises SEK 96 million in a share issue led by Industrifonden and Investinor

Industrifonden and Investinor of Norway are investing a combined SEK 79 million in the specialty pharma company Pharmalink. Private investors are also participating in the share issue, which totals SEK 96 million. The money will be used for the further development of Pharmalink’s product portfolio.Pharmalink is a specialty pharma company that improves and refines existing drugs. Its current projects are Nefecon as a treatment for nephritis and Busulipo as a treatment for bone marrow transplantation. The company is raising capital now in order to implement clinical studies of Nefecon and